|Manufacturer||Intas Pharmaceuticals Ltd|
|Packaging Type||Vial with stopper|
|Active Ingredient||liposomal amphotericin|
We are one of the leading supplier of Liposomal Amphotericin-B. These products are formulated at par with the international standards of quality. Our products are processed using the superior quality ingredients, which makes these highly demanded & effective. These products are available at the most nominal prices and hold the following various sizes:
Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.
Safety controversyIn April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties. A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.
COVID-19In late July 2020 Merck, which had been partnering with Ridgeback Biotherapeutics on developing the drug, announced its intention to move molnupiravir to late stage trials beginning in September 2020. On October 19 2020, Merck began a one year Stage 2/3 trial focused on hospitalized patients.
|Packaging Size||1 X 34|
Fabiflu Favipiravir 200mg Tablets
Covid 19 treatment
Favipiravir UsesFavipiravir is used in the treatment of Coronavirus disease (COVID-19).How Favipiravir worksFavipiravir is an antiviral medicine. It stops the SARS-CoV-2 virus from multiplying. By doing so, it decreases viral load in the body, restricts the spread of infection and helps in speeding up the recovery process.
|Number of Syringe||2 Pre-Filled Syringe|
|Dosage/Strength||40 mg/0.4 ml|
|Drug Type||Anticoagulant Drug|
|Manufacturer Name||Sanofi India Ltd|
|Prescription/ Non Prescription||Prescription|
|Usage||Treatment and prevention of blood clots|
|Minimum Order Quantity||10 Box|
|Product Type||Finished Product|
New Pack posphop
Picasa, Noxafil, Posanat,
Unilastatin 100000IU Injection is used in the treatment of severe sepsis and inflammation of the pancreas (acute pancreatitis). It helps to reduce the chemicals involved in the inflammation of the pancreas.
Reviewed by 194 Users
Most Relevant Reviews